NeoPharm CO., LTD. (KOSDAQ:092730)

South Korea · Delayed Price · Currency is KRW

23,150

-1,100 (-4.54%)

Oct 8, 2026, 3:30 PM KST

Market Cap	362.10B +33.9%
Revenue (ttm)	132.18B +11.1%
Net Income	27.82B +20.6%
EPS	1,778.81 +20.6%
Shares Out	15.64M
PE Ratio	13.01
Forward PE	10.04
Dividend	750.00 (3.24%)
Ex-Dividend Date	Dec 29, 2025

Volume	35,779
Open	24,000
Previous Close	24,250
Day's Range	23,000 - 24,200
52-Week Range	15,590 - 26,000
Beta	0.54
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About NeoPharm CO., LTD.

NeoPharm CO., LTD. engages in the manufacturing and sale of skin care products in South Korea. The company provides Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand name; sensitive, dry, oily, or trouble-prone skin care products under the ZEROID brand; body moisturizers under the Derma-B brand name; sport care products under the MISSION ATHELETCARE brand; and dermArtlogy, a 1:1 consulting cosmetic brand. NeoPharm CO., LTD. was founded in 2000 and is headquartered in Daejeon, So... [Read more]

Industry Household & Personal Products

Sector Consumer Staples

Founded 2000

Employees 178

Stock Exchange KOSDAQ

Ticker Symbol 092730

Full Company Profile

Financial Performance

In 2025, NeoPharm CO., LTD.'s revenue was 132.18 billion, an increase of 11.07% compared to the previous year's 119.01 billion. Earnings were 27.82 billion, an increase of 20.63%.

Financial Statements